Document Detail


Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.
MedLine Citation:
PMID:  12597144     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM AND BACKGROUND: To evaluate feasibility of neoadjuvant chemotherapy (NA-CT) followed by CT + radiotherapy (RT) in locally advanced or unresectable head and neck squamous cell carcinoma (HNSCC). METHODS: 22 HNSCC patients were enrolled (18 males, 4 females; median age, 59.5 years; median ECOG PS, 1). Sites of disease: oral cavity, 18.2%; oropharynx, 40.9%; hypopharynx, 18.2%; larynx, 4.6%, multiple sites, 18.2%. T (tumor) category: T2, 13.6%; T3, 31.8%; T4, 54.5%. N (nodes) category: NO, 9.1%; N1, 18.1%; N2, 40.9%; N3, 31.8%. Stage: III, 4.6%; IVA, 63.6%; IVB, 31.8%. Induction carboplatin (AUC = 6) and paclitaxel (200 mg/m2) x 3 cycles (q21 days) were given. Responders received definitive radiotherapy with concurrent carboplatin (35 mg/m2/day from days 1 to 5 in weeks 1, 3, 5 and 7) and paclitaxel (50 mg/m2 on days 10, 24 and 38). Patients with node involvement were suggested to undergo postradiotherapy neck dissection. RESULTS: NA-CT. 97% of planned chemotherapy cycles were administered. Prevalent toxicity was hematologic: 50% G4 neutropenia and 31.8% G3, one neutropenic fever. All patients had alopecia. Complete responses in T and N were 4 (18.2%) and 3 (15%), respectively. Partial responses were 13(59%) and 9 (45%). There was 1 progressive disease. CT + RT. 79.9% of planned cycles of CT were administered. In 19 patients (86.4%) more than 50% of planned cycles of CT were completed. Median dose of RT was 70.2 Gy on T/N+ and 54 Gy on NO. Limiting toxicity was mucositis in 77.3%, followed by neutropenia (59.1% G3-G4). Median weight loss was 4.9%.18.2% of patients required hospitalization. Complete responses in T and N were 15 (68.1%) and 8 (40%), respectively. Partial responses were 5 (22.7%) and 7 (35%). CONCLUSIONS: The preliminary results of this study are encouraging, despite the toxicity. Adequate follow-up is required to evaluate efficacy in terms of local-regional control and overall survival.
Authors:
Gianni Fornari; Elisa Artusio; Lorenza Mairone; Mario Airoldi; Guido Bongioannini; Enrica Amasio; Claudia Rosmino; Pietro Gabriele
Related Documents :
12926104 - Phase i study of pegylated liposomal doxorubicin (caelyx) in combination with carboplat...
9020284 - Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lun...
11576264 - Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy...
2655094 - Optimal dosing with carboplatin.
8343264 - The changing importance of prognostic factors in bladder cancer during a long-term foll...
18003624 - Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ov...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Tumori     Volume:  88     ISSN:  0300-8916     ISO Abbreviation:  Tumori     Publication Date:    2002 Nov-Dec
Date Detail:
Created Date:  2003-02-24     Completed Date:  2003-03-11     Revised Date:  2008-12-12    
Medline Journal Info:
Nlm Unique ID:  0111356     Medline TA:  Tumori     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  489-94     Citation Subset:  IM    
Affiliation:
Oncology Division, Ospedale Evangelico Valdese, Torin, Italy. fornarig@sirio-oncology.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carboplatin / administration & dosage
Carcinoma, Squamous Cell / drug therapy*,  pathology,  radiotherapy*,  surgery
Chemotherapy, Adjuvant / adverse effects
Drug Administration Schedule
Feasibility Studies
Female
Head and Neck Neoplasms / drug therapy*,  pathology,  radiotherapy*,  surgery
Humans
Male
Middle Aged
Neoadjuvant Therapy / adverse effects
Paclitaxel / administration & dosage
Radiotherapy, Adjuvant / adverse effects
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
33069-62-4/Paclitaxel; 41575-94-4/Carboplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of the evolution in the management of endometrial cancer in Italy: a CTF study.
Next Document:  Hormono-radiotherapy in prostatic carcinoma: prognostic factors and implications for combined modali...